Septerna, Inc. (SEPN) Stock Price & Analysis
Septerna, Inc. (SEPN) rose 1.97% to USD 31.01 as of June 10, 2026 at 04:33 UTC, according to Nexqual real-time market data.
SEPN last closed at USD 30.41; the session ranged USD 30.3–31.9 on volume of 268,361 shares. Market capitalization is $1.40B, with a 52-week range of USD 9.85–32.63 (NGM). Source: Nexqual, June 10, 2026 at 04:33 UTC.
Key Statistics (as of June 10, 2026 at 04:33 UTC)
| Price | USD 31.01 |
|---|---|
| Change | ▲ 1.97% (up) |
| Previous Close | USD 30.41 |
| Open | USD 30.69 |
| Day Range | USD 30.3 – 31.9 |
| 52-Week Range | USD 9.85 – 32.63 |
| Volume | 268,361 shares |
| Market Cap | $1.40B |
| Exchange | NGM |
Technical Analysis (SEPN)
Nexqual's technical model rates SEPN "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 04:33 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.93 (neutral) |
| vs SMA50 | Above (USD 26.16) |
| MACD | 1.49 (positive) |
Analyst Ratings (SEPN)
Wall Street analysts rate SEPN "Strong Buy" based on 8 analysts, with a mean price target of USD 45 (range USD 35–60), per Nexqual as of June 10, 2026 at 04:33 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 45 |
| High Target | USD 60 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (SEPN)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.49 |
| Revenue Estimate | $16.42M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.19 vs est -0.27 ▲ beat |
| 2025-12-31 | USD -0.24 vs est -0.22 ▼ miss |
| 2025-09-30 | USD -0.1 vs est 0.79 ▼ miss |
| 2025-06-30 | USD -0.56 vs est 0.93 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:33 UTC.
Financials & Fundamentals (SEPN)
| Total Revenue | $72.25M |
|---|---|
| Revenue Growth (YoY) | +12011.00% |
| Gross Margin | +100.00% |
| Operating Margin | -50.14% |
| Profit Margin | -49.88% |
| ROE | -9.26% |
| Debt / Equity | 6.1 |
| Current Ratio | 4.71 |
| Total Cash | $347.40M |
| Total Debt | $23.09M |
| Free Cash Flow | $24.01M |
Source: Nexqual, June 10, 2026 at 04:33 UTC.
Financial Health Score (SEPN)
Nexqual rates Septerna, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:33 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $347M cash vs $23M debt, net cash position |
| Cash Flow | Strong — FCF $24M, 52% margin |
| Efficiency | Critical — ROE -9%, ROA -8.5% |
Ownership (SEPN)
| Insider Ownership | +3.17% |
|---|---|
| Institutional Ownership | +102.63% |
| Shares Outstanding | 45.08M |
| Float | 23.12M |
| Short % of Float | +11.47% |
Source: Nexqual, June 10, 2026 at 04:33 UTC.
Leadership (SEPN)
Septerna, Inc. is led by Jeffrey T. Finer (age 58), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 04:33 UTC.
| Co-Founder, CEO & Director | Jeffrey T. Finer (age 58) |
|---|---|
| President & COO | Elizabeth P. Bhatt M.B.A., M.S. (age 57) |
| Chief Financial Officer | Gilbert M. Labrucherie C.F.A. (age 53) |
| Vice President of Technology | Richard Hansen |
| Senior Director of Corporate Development & Portfolio Strategy | George Xu |
Major Backers & Investors (SEPN)
Notable institutional backers of Septerna, Inc. include Trv Gp V, LLC , RA Capital Management, L.P., Driehaus Capital Management, LLC, according to Nexqual as of June 10, 2026 at 04:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Trv Gp V, LLC | 23.13% |
| RA Capital Management, L.P. | 15.52% |
| Driehaus Capital Management, LLC | 9.75% |
| Samsara BioCapital, LLC | 6.99% |
| Goldman Sachs | 6.45% |
| Siren, L.L.C. | 4.44% |
| BVF Inc. | 3% |
| Avoro Capital Advisors LLC | 2.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.01% |
| Vanguard Group | 2.58% |
Source: Nexqual, June 10, 2026 at 04:33 UTC.
From Septerna, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
- It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
- In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease.
- It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBX | MBX Biosciences, Inc. | USD 29.87 | ▼ 1.35% |
| UPB | Upstream Bio, Inc. | USD 6.69 | ▼ 5.11% |
| RAPP | Rapport Therapeutics, Inc. | USD 35.84 | ▼ 0.72% |
| BCAX | Bicara Therapeutics Inc. | USD 20.56 | ▲ 2.8% |
| ALMS | Alumis Inc. | USD 20.01 | ▲ 4.98% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:33 UTC. This page is informational and not investment advice.